# mRNA-1010

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/mrna-1010
Canonical HTML page: https://getfinancebrief.com/entity/mrna-1010

## Timeline

- **2026-02-18**: FDA U-Turn — Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval.
- **2026-02-15**: Public Dispute — Moderna and administration officials engage in a public disagreement over the regulatory path forward.
- **2026-02-10**: Initial Rejection — Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing.

## Recent coverage (2 stories)

### FDA Reverses Stance on Moderna’s mRNA Flu Shot, Clearing Path for Review
2026-02-18 21:43:09 · Sentiment: Bullish · Impact: 7/10 · Sources: 3

The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
Full story: https://getfinancebrief.com/story/fda-reversal-moderna-mrna-flu-shot-review

### FDA Reverses Course on Moderna mRNA Flu Shot After Controversial Rejection
2026-02-18 18:57:55 · Sentiment: Bullish · Impact: 8/10 · Sources: 6

The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline.
Full story: https://getfinancebrief.com/story/fda-moderna-flu-shot-reversal

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.